Omega-3 supplements are sold as if EPA and DHA were interchangeable ingredients. They are not. They are related long-chain fats, usually found together in fish oil, but the evidence for each one depends on the outcome, the dose, and whether the product is a licensed medicine or a supplement on a shop shelf.
The useful question is not whether omega-3s are “good”. It is which omega-3, in what form, for which person, and with what risks attached. That distinction matters because the evidence is strongest for treating high triglycerides under medical supervision, more mixed for general heart protection, and still unusually vulnerable to product-quality problems.
EPA and DHA do different jobs
EPA, or eicosapentaenoic acid, and DHA, or docosahexaenoic acid, are both long-chain marine omega-3 fatty acids. The body can make small amounts from ALA, the plant omega-3 found in flax, chia, and walnuts, but conversion is limited, especially for DHA. That is why fatty fish, seafood, fortified foods, algae oil, and fish-oil supplements receive most of the attention.
DHA is a structural fat. It is concentrated in the brain and retina, and it is particularly relevant during pregnancy and early development. EPA is less of a structural building block and more often discussed for lipid and inflammatory signalling pathways. That does not make EPA the “heart” omega-3 and DHA the “brain” omega-3 in any simple consumer sense. Most foods and many supplements contain both, and human trials often test combinations.
The NIH Office of Dietary Supplements fact sheet is useful because it keeps these categories separate: ALA, EPA, and DHA are related, but they are not dose-for-dose substitutes. A capsule label that says “1,000 mg fish oil” may deliver far less EPA plus DHA than a reader assumes.
Food evidence is not the same as capsule evidence
Eating fish is not biologically identical to swallowing isolated fish oil. Fish supplies protein, selenium, iodine, vitamin D in some species, and a food pattern that may displace processed meat. Fish-oil capsules supply fatty acids, and sometimes not much else. That distinction is one reason nutrition evidence often looks stronger for dietary patterns than for single-nutrient supplements.
For adults without a specific triglyceride indication, the cardiovascular case for over-the-counter omega-3 capsules is modest. NCCIH’s omega-3 supplement summary notes that supplements have not consistently shown protection against heart disease outcomes in the general population, even though seafood intake remains part of many heart-healthy dietary patterns.
This is where Theo Marsh’s supplement rule applies: first separate the compound from the product. EPA and DHA are real nutrients. Fish oil as a commercial category is a mixed bag. A person eating oily fish twice a week, a pregnant person considering algae-derived DHA, and a patient prescribed high-dose icosapent ethyl for triglycerides are not making the same decision.
Prescription omega-3s are a different category
The strongest dose-specific evidence sits in prescription treatment for high triglycerides, not in general wellness dosing. The American Heart Association’s science advisory on omega-3 fatty acids for hypertriglyceridaemia describes 4 g/day prescription omega-3 therapy as an evidence-based triglyceride-lowering option for selected patients, used alongside diet and standard medical care.
That does not mean four grams of any fish-oil supplement is an equivalent intervention. Prescription products have defined active ingredients, manufacturing controls, dosing instructions, and adverse-event monitoring. Over-the-counter supplements vary in EPA and DHA concentration, oxidation, capsule count, and label clarity. Some also contain vitamin A or other added ingredients that change the safety profile.
There is also a difference between mixed EPA/DHA products and purified EPA. In REDUCE-IT, a high-risk cardiovascular outcomes trial, icosapent ethyl, a prescription EPA product, reduced major cardiovascular events in statin-treated patients with elevated triglycerides. That result is important. It should not be casually transferred to every fish-oil capsule.
Later trial evidence makes the category more complicated. The STRENGTH trial tested a high-dose EPA/DHA carboxylic-acid formulation in statin-treated patients at high cardiovascular risk and was stopped early for low likelihood of benefit. Possible explanations include EPA-only versus EPA/DHA, achieved blood levels, trial design, comparator oils, patient selection, or chance. The honest conclusion is narrower than the marketing: prescription omega-3 therapy may have a role in specific lipid-management settings, but low-dose mixed fish oil has not become a general heart drug.
This distinction is especially important for readers already taking statins, blood-pressure medicines, anticoagulants, or diabetes drugs. Omega-3 supplements are often treated as background nutrition, but at pharmacological doses they become part of a treatment plan and should be discussed as such.
Dose should be counted as EPA plus DHA
Most supplement labels require arithmetic. A front label may say 1,000 mg fish oil, while the Supplement Facts panel lists 180 mg EPA and 120 mg DHA. In that example, the clinically relevant combined EPA plus DHA is 300 mg, not 1,000 mg. Concentrated products may contain much more per capsule, but the only reliable way to know is to read the back label.
For general adults, there is no longevity-specific omega-3 dose with outcome evidence strong enough to recommend self-prescribing. For triglyceride lowering, the evidence-supported prescription range is usually discussed around 4 g/day under clinical supervision. For pregnancy, the context shifts again: DHA intake may matter for foetal neurodevelopment, but fish choice, mercury exposure, vitamin A from cod-liver oil, nausea, and existing medical conditions all affect the decision.
High-dose intake also changes the risk conversation. The NIH Office of Dietary Supplements notes that the US Food and Drug Administration has advised that no more than 5 g/day of EPA and DHA combined should come from dietary supplements, but that safety boundary is not the same as saying high doses are appropriate for everyone.
Quality control is part of the evidence
Fish oil is chemically fragile. Polyunsaturated fats oxidise when exposed to oxygen, heat, and light. The result may be rancid odour, off-flavours, and uncertain biological effects. Independent studies have not always agreed on how common the problem is, partly because testing methods and markets differ, but quality variation is real enough to treat as part of the intervention.
A multi-year rancidity analysis of marine and microalgal oil supplements reported measurable oxidation concerns across sampled products. Older studies have found both failures and more reassuring results in different markets. The practical point is not that every product is bad; it is that a supplement is not automatically equivalent to the molecule named on the label.
Quality markers worth looking for include clear EPA and DHA amounts, lot-specific third-party testing, oxidation testing, contaminant testing for heavy metals and PCBs, reasonable expiry dating, and packaging that limits heat and light exposure. None of these proves clinical benefit. They only make it more likely that the product contains what it claims.
Safety: bleeding, surgery, and atrial fibrillation
Omega-3s can affect platelet function, which is why bleeding warnings appear on many labels. In ordinary dietary amounts, this is rarely the headline risk. At higher supplemental or prescription doses, the caution becomes more relevant for people taking warfarin, direct oral anticoagulants, antiplatelet drugs, high-dose NSAIDs, or those preparing for surgery. This is a clinician conversation, not a supplement-counter decision.
A second safety signal has become harder to ignore: atrial fibrillation. A 2021 dose-related meta-analysis in Circulation found a higher atrial fibrillation risk signal in trials of omega-3 fatty acids, especially at larger doses. REDUCE-IT also reported more atrial fibrillation or flutter requiring hospitalisation in the icosapent ethyl group, alongside the cardiovascular event reduction.
That trade-off does not make prescription EPA a bad treatment. It means benefit and risk have to be weighed for the person in front of the clinician. Someone with prior atrial fibrillation, palpitations, anticoagulant use, upcoming surgery, bleeding disorders, fish allergy, or pregnancy should not treat high-dose omega-3s as casual wellness pills.
What this means in practice
- Separate food from supplements: oily fish and seafood sit inside a broader dietary pattern; capsules are isolated products with their own quality issues.
- Read the Supplement Facts panel for EPA and DHA, not just the front-label fish-oil number.
- Do not extrapolate REDUCE-IT to generic fish oil; it studied prescription icosapent ethyl in a high-risk group.
- Ask a clinician before using high-dose omega-3s if you take anticoagulants or antiplatelets, have atrial fibrillation, are pregnant, or have surgery planned.
- For supplements, favour products that publish third-party testing for EPA/DHA content, oxidation, and contaminants.
- Treat triglyceride lowering as medical care. Prescription omega-3 dosing is not the same category as everyday nutrition.
What we don’t know
We do not have a clean longevity trial showing that healthy adults who add an ordinary fish-oil supplement live longer, age more slowly, or avoid cardiovascular disease. We also do not know whether small differences in consumer supplement oxidation meaningfully change long-term outcomes. Most studies are too short, too heterogeneous, or too dependent on intermediate markers.
We know more about triglyceride lowering than about broad prevention. We know more about prescription products than about the average capsule sold online. And we know enough about atrial fibrillation and bleeding cautions to resist the idea that “natural” means risk-free.
The best reading of omega-3 evidence is therefore conditional. EPA and DHA matter. Fish can be a useful food. Prescription omega-3s have a defined clinical role. Over-the-counter capsules deserve a narrower, more sceptical claim: possibly useful for selected people, but not a universal longevity shortcut.
Photo: Olga Kovalski on Unsplash.